September 11, 2012 Program
Letter from New York City Mayor’s office:
Keynote Speaker: Robert K. Weiss, President XPrize (Los Angeles, CA)
Mr. Robert K. Weiss is the Vice Chairman and President of the XPRIZE (www.xprize.org), the leading organization solving the world’s Grand Challenges by creating and managing large-scale, high-profile, incentivized prize competitions that stimulate investment in research and development worth far more than the prize itself. The organization motivates and inspires brilliant innovators from all disciplines to leverage their intellectual and financial capital for the benefit of humanity. The XPRIZE conducts competitions in five Prize Groups: Education; Exploration; Energy & Environment; Global Development; and Life Sciences. Prizes won include the $10 million Ansari XPRIZE for private, suborbital space flight; the $10 million Progressive Insurance Automotive XPRIZE for creating safe, affordable, production-capable vehicles that exceed 100 MPGe (energy equivalent); the $2 million Northrop Grumman Lunar Lander XCHALLENGE for advanced rocket development; and the $1.4 million Wendy Schmidt Oil Cleanup XCHALLENGE for highly effective, ocean surface oil spill cleanup methods. Active prizes include the $30 million Google Lunar XPRIZE, the $10 million Archon Genomics XPRIZE presented by Express Scripts, and the $10 million Qualcomm Tricorder XPRIZE, and the $2.25 million Nokia Sensing XCHALLENGE.
Mr. Weiss is a veteran Hollywood television and film producer having produced more than 20 feature films and TV series during the past 25 years. He began his career in the late 1970’s producing the feature film, KENTUCKY FRIED MOVIE and later produced the ABC television program POLICE SQUAD! as well as the three NAKED GUN movies starring Leslie Nielsen. Mr. Weiss produced the international hit, THE BLUES BROTHERS for Universal Studios. His other feature films produced for Universal include AMAZON WOMEN ON THE MOON and DRAGNET. He was the Executive Producer for the television series WEIRD SCIENCE and SLIDERS (that he co-created) as well as served as a consultant and team partner to the Boeing Corporation in the development of a global consortium dedicated to the distribution of space related multimedia entertainment and educational programs, products and services. Additionally, he served as Executive Producer for the American Rocket Company producing multimedia connected with the development, testing and launch attempt of their pioneering hybrid rocket. Mr. Weiss served on the Board of Directors of IS Robotics (now called iRobot in Cambridge, Massachusetts) from 1990 to 1994. In 2000, he was Executive Vice President and Executive Producer for the Blastoff Corporation in Pasadena, California; an entertainment company founded to conduct actual space missions as the Foundation for high value media and marketing platforms. Mr. Weiss has been the President of the XPRIZE since July 2008.
Heat Biologics (“Heat”) is a clinical-stage company focused on developing its novel “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) off-the-shelf therapeutic vaccines to combat a wide range of cancers and other diseases. Heat’s ImPACT therapy effectively transforms living tumor cells into powerful machines that “pump out” important antigens to robustly stimulate the immune system against the targeted disease.
Jeff Wolf is the Founder and President of Heatbiologics and former managing director at Seed-One Ventures, a firm focused on identifying and acquiring cutting-edge ideas and technologies and the systematic formation and management of early-stage, high-growth companies based on these breakthroughs. Jeff’s primary area of focus is forming and running new technology-based ventures. Since founding Seed-One, Jeff has started and run several medical and biotech companies. Jeff’s start-ups include Avigen, a San Francisco-based gene therapy company; TyRx which is focused on the development of bio-compatible polymers; EluSys Therapeutics, a New Jersey company focused on the development of a novel technology to remove blood-borne pathogens; Sensatex, a Maryland company focused on the development of novel medical diagnostic systems and GenerationOne, a Miami-based company focused on mobile-based collaborative care.
Jeff received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics.
Fred Colen, CEO Benechill (San Diego, CA)
BeneChill, a privately held medical device company, was established in 2004 to develop, manufacture, and sell novel rapid cooling technologies that increase the rate of neurologically intact survival after an ischemic event, such as cardiac arrest.
BeneChill’s groundbreaking technology, the RhinoChill® IntraNasal Cooling System is designed to deliver effective cooling faster and earlier than conventional cooling methods. Through a lightweight, portable design and unique intra-nasal delivery of a proprietary coolant, the RhinoChill® System enables both rescue services and hospital personnel to easily and effectively initiate cooling.
Fred Colen is an experienced MedTech business executive, who successfully led small, medium and multi-billion dollar medical device companies around the world. He has developed a reputation for innovation and successful commercialization of new medical technology products. Until recently he was the President of Boston Scientifics’ Cardiac Rhythm Management Group.
He furthermore served as Boston Scientifics’ Chief Technology Officer for eight years. Born and raised in the Netherlands, he obtained a Masters Degree in Electrical Engineering with specialization in BioMedical Technology from the RWTH Aachen, Germany. He is currently the CEO of BeneChill and serves as a Board Member for Molnlycke Healthcare and as an advisor to the Xeltis Board.
mivenion GmbH is a life-science company focusing on personalized medicine for patients with inflammatory and autoimmune diseases. With its strong expertise in both pharmaceuticals and medical devices, mivenion is providing cutting edge solutions for life-long patient care.
Xiralite, the leading product of mivenion, enables the Rheumascan procedure. It provides for the first time an integrated solution for patients with inflammatory diseases in the hands. Based on optical technologies, active inflammation is diagnosed at a very early stage with confidence, attractive technical ease, and high patient comfort.
Malte Bahner is one of mivenion’s co-founders. From 1990 until 2001 he held several positions in clinical medicine and in diagnostic radiology, both in more clinical and more scientifically oriented institutions. In 2001, Dr. Bahner joined Schering AG, where he was involved in all aspects of clinical development of different diagnostic agents. Malte Bahner is board certified for Diagnostic Radiology, for Physician Quality Management, holds a degree in Betriebswirtschaft (IWW), and is a member of the Medical Faculty of the Ruprecht-Karls University (Heidelberg).